Surgeon in a surgical cap and mask operating under bright theatre lights in a dark operating room

Case 01

/

HEALTH + SCIENCE

Sylke logo: white SYLKE lettering beside a blue and white woven-mesh symbol

Make the upstart impossible to dismiss.

A plastic surgeon with a radically different approach to surgical closure set out to transform an industry dominated by global healthcare giants. Bringing his vision to life meant earning the trust of surgeons, hospital decision-makers, procurement teams and investors.

Sylke surgical closure story: surgeons in green scrubs and masks operating under bright light, with the Sylke logo and its woven mesh symbol across the frame
Close-up of a fine woven mesh fabric in dark, raking light

01 / Assessment

Make the difference tangible.

We used Sylke's origin, craftsmanship and science to establish its value, creating room for surgeons and gatekeepers to see the possibility of better outcomes.

Close-up of a fine woven mesh fabric in dark, raking light

01 / Assessment

Make the difference tangible.

We used Sylke's origin, craftsmanship and science to establish its value, creating room for surgeons and gatekeepers to see the possibility of better outcomes.

Raw silk fibres lit in warm golden light

02 / Aperture

Follow the product.

From an Indian silk farm to a Milanese mill, a Cambridge clean room and the operating room, we brought provenance, craftsmanship, science and patient care to life.

Raw silk fibres lit in warm golden light

02 / Aperture

Follow the product.

From an Indian silk farm to a Milanese mill, a Cambridge clean room and the operating room, we brought provenance, craftsmanship, science and patient care to life.

Surgical tweezers placing a stitch in teal surgical cloth

03 / Activation

Credibility where it counts.

We focused on earning trust and trial through targeted surgeon meetings, hospital procurement conversations, investor presentations and industry conferences.

Surgical tweezers placing a stitch in teal surgical cloth

03 / Activation

Credibility where it counts.

We focused on earning trust and trial through targeted surgeon meetings, hospital procurement conversations, investor presentations and industry conferences.

THE PROOF

$100-150M → $800M-1.5B

EST. VALUATION SINCE ENGAGEMENT

1M+

PATIENTS

27

COUNTRIES

“The quality of this production exceeds anything [global medical-device executives] have ever produced.”

M. MARK MOFID, MD, FACS / PRESIDENT + CEO, SYLKE

THE PROOF

$100-150M → $800M-1.5B

EST. VALUATION SINCE ENGAGEMENT

1M+

PATIENTS

27

COUNTRIES

“The quality of this production exceeds anything [global medical-device executives] have ever produced.”

M. MARK MOFID, MD, FACS / PRESIDENT + CEO, SYLKE

THE PROOF

$100-150M → $800M-1.5B

EST. VALUATION SINCE ENGAGEMENT

1M+

PATIENTS

27

COUNTRIES

“The quality of this production exceeds anything [global medical-device executives] have ever produced.”

M. MARK MOFID, MD, FACS / PRESIDENT + CEO, SYLKE

What are you trying to make possible?

Let’s find the story that moves it forward.

New York

San Francisco

Los Angeles

hello@incahootsstudio.com

incahootsstudio.com